Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma

BACKGROUND: Lenvatinib combined with programmed cell death protein-1 (PD-1) inhibitors has resulted in good survival outcomes in the treatment of unresectable hepatocellular carcinoma (HCC). Hepatic artery infusion chemotherapy (HAIC) has also attracted attention due to its high response rates and f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Jie, Tang, Yu-Hao, Wei, Wei, Shi, Ming, Zheng, Lie, Li, Shao-Hua, Guo, Rong-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947809/
https://www.ncbi.nlm.nih.gov/pubmed/33718175
http://dx.doi.org/10.3389/fonc.2021.618206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947809/
https://www.ncbi.nlm.nih.gov/pubmed/33718175
http://dx.doi.org/10.3389/fonc.2021.618206

Ejemplares similares